Tabula Rasa Healthcare

Tabula Rasa Healthcare, Inc. is a healthcare technology company, which engages in the development of solutions designed for pharmacists, providers, and patients to optimize medication regimens. It operates through the following segments: CareVention HealthCare and MedWise HealthCare. The CareVention HealthCare segment provides services, PACE, which is a center for Medicare & Medicaid services, or CMS, sponsored program providing medical and social services. Its brands include CareKinesis, Capstone Risk Adjustment Services, PACElogic, TruChart, PeakTPA, PersonifilRx, and Pharmastar. The MedWise HealthCare segment provides Medication Therapy Management, or MTM, software and services for Medicare, Medicaid, and commercial health plans, and also provides a cloud-based patient engagement software and services. It offers cloud-based software and clinical pharmacist services through its brands, including MedWise, SinfoníaRx, RxCompanion, PrescribeWellness, and DoseMeRx. The company was founded by Calvin H. Knowlton, Orsula V. Knowlton, and Michael Greenhalgh in April 2009 and is headquartered in Moorestown, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Tabula Rasa HealthCare reports robust Q4 growth and strategic investments

Tabula Rasa HealthCare's Q4 2022 performance reflects strong revenue growth and strategic initiatives to enhance profitability.
While facing challenges in technology-enabled solutions revenue and execution risks, the company is well-positioned for growth.
Opportunities in automation investments and MedWise platform expansion offer avenues for sustained revenue growth and market impact.

Tabula Rasa HealthCare (TRHC) excels in Q1 2023 earnings, eyes expansion

Tabula Rasa HealthCare (TRHC) delivered strong financial performance in Q1 2023, driven by revenue growth, profitability focus, and strategic initiatives.
The company faces challenges from drug price inflation and contract turnover impact but is well-positioned for future expansion and market penetration.
TRHC's emphasis on customer-centric strategies, PACE program growth, and efficient resource management sets the stage for continued success and revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tabula Rasa provides state-of-the-art medication management through a combination of technology, science and services that reduces costs, improves the quality of care and decreases the risks associated with ineffective medication plans.

A study from the British Journal of Clinical Pharmacology increases awareness of the applicability of a Bayesian method in healthcare settings A study from the British Journal of Clinical Pharmacology increases awareness of the applicability of a Bayesian method in healthcare settings

Tabula Rasa HealthCare’s DoseMe® Bayesian Forecasting Method Receives Rating of Most User-Friendly in Clinical Study

Partnership focuses on care and cost in health plans Partnership focuses on care and cost in health plans

TRHC and Troy Medicare Leverage Technology to Provide Innovative Care Coordination

MOORESTOWN, N.J., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, today announced that Chief Financial Officer, Brian W. Adams, and Chief Accounting Officer, Andrea Speers, MS, will participate in upcoming investor conferences.

Tabula Rasa HealthCare to Participate in Upcoming Investor Conferences

Bull of the Day: Tabula Rasa Healthcare (TRHC)

MOORESTOWN, N.J., Aug.  22, 2019  (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced a partnership between its precision dosing software subsidiary DoseMe and Bainbridge Health, a Children’s Hospital of Philadelphia (CHOP) spin-off. “Managing medications to prevent patient harm and to reduce waste is an incredibly complex and challenging process for hospital clinicians,” said Joseph Kaupp, Co-founder and CEO of Bainbridge Health. “In pursuit of our mission to distill that complexity in order to improve safety and eliminate avoidable cost, it is crucial to partner with mission-aligned industry leaders to continually innovate and drive value. We are privileged to have such a partner in DoseMe and look forward to working together to reduce cost and - most importantly - improve the safety and quality of patient care.” Bainbridge Health provides clinical solutions based on more than a decade of research and development, including the Med O.S® medication safety and stewardship platform that reduces the risk of medication errors and waste. The partnership will leverage Bainbridge Health’s Med O.S® platform to further enhance medication safety and reduce costs across DoseMe’s partner hospitals.  DoseMeRx is a precision dosing software that was developed specifically for clinical practice. It is a simple, yet powerful tool helping healthcare providers calculate the optimal dose of drugs monitored by therapeutic drug monitoring to streamline operations, reduce adverse drug events, decrease costs, and improve patient outcomes. "The precision dosing capabilities of DoseMeRx, combined with Bainbridge's platform, will provide new insights into optimizing intravenous medications in the acute care setting,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD.  “By bringing together our technologies, we increase the potential to support healthcare organizations to ensure medications are being appropriately prescribed and delivered to patients in the safest possible manner to improve medication stewardship, reduce adverse drug events and decrease the workload for pharmacy and nursing.” “We are excited to partner with Bainbridge Health which has a long history and expertise in collaborating with adult and pediatric health systems to enhance medication safety and stewardship,” added Charles Cornish, CEO, DoseMe. “For those hospitals and infusion centers that choose our combined offering, we expect they will see a further enhancement in dosing performance while freeing up nurses and pharmacists to practice at the top of their licenses.”

Bainbridge Health Partners with Tabula Rasa HealthCare’s subsidiary DoseMe  To Expand Medication Management Capabilities to Health System(s)

CEO of Tabula Rasa Healthcare Inc (30-Year Financial, Insider Trades) Calvin H Knowlton (insider trades) sold 8,000 shares of TRHC on 08/19/2019 at an average price of $64.13 a share.

Tabula Rasa Healthcare Inc (TRHC) CEO Calvin H Knowlton Sold $513,040 of Shares

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of 600.00% and 8.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Tabula Rasa Healthcare (TRHC) Surpasses Q2 Earnings and Revenue Estimates

CFO of Tabula Rasa Healthcare Inc (30-Year Financial, Insider Trades) Brian W Adams (insider trades) sold 10,000 shares of TRHC on 07/31/2019 at an average price of $60 a share.

Tabula Rasa Healthcare Inc (TRHC) CFO Brian W Adams Sold $600,000 of Shares

Tabula Rasa HealthCare, Inc. (TRHC) CEO Calvin Knowlton on Q1 2019 Results - Earnings Call Transcript

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of 66.67% and 2.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Tabula Rasa Healthcare (TRHC) Q1 Earnings and Revenues Surpass Estimates

Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Tabula Rasa Healthcare (TRHC) Q1 Earnings Expected to Decline

Cerner

CERN vs. TRHC: Which Stock Is the Better Value Option?

News for Tabula Rasa Healthcare Stock (TRHC)